Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 127, Issue 3, Pages 737-749Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI84417
Keywords
-
Categories
Funding
- Public Health Service [F32 AI096833, R01 AI123348, U54 AI057157]
Ask authors/readers for more resources
Chikungunya virus (CHIKV), a reemerging arbovirus, causes a crippling musculoskeletal inflammatory disease in humans characterized by fever, polyarthralgia, myalgia, rash, and headache. CHIKV is transmitted by Aedes species of mosquitoes and is capable of an epidemic, urban transmission cycle with high rates of infection. Since 2004, CHIKV has spread to new areas, causing disease on a global scale, and the potential for CHIKV epidemics remains high. Although CHIKV has caused millions of cases of disease and significant economic burden in affected areas, no licensed vaccines or antiviral therapies are available. In this Review, we describe CHIKV epidemiology, replication cycle, pathogenesis and host immune responses, and prospects for effective vaccines and highlight important questions for future research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available